Boehringer Ingelheim expands collaboration with Vanderbilt University to tackle some of the most difficult-to-treat cancers

Boehringer IngelheimBoehringer Ingelheim has announced a new collaboration with Vanderbilt University, Nashville, Tennessee. The multi-year program complements an already existing collaboration by focusing on the research and development of small molecule compounds targeting the protein SOS (Son Of Sevenless). This molecule activates KRAS, a molecular switch that plays a central role in the onset of some of the deadliest cancers.

The collaboration combines pioneering research in the laboratory of Stephen W. Fesik, Orrin H. Ingram II professor in cancer research at Vanderbilt University, with the unique expertise and strength of Boehringer Ingelheim in drug discovery and clinical development. The new collaboration adds to an ongoing joint project with Vanderbilt University initiated in 2015 that achieved two major milestones by identifying lead compounds that bind to KRAS with high affinities. These discoveries raise the prospect of developing novel cancer treatment options based on molecules that are able to block this critical cancer driver.

"We are very encouraged by the successful identification of inhibitors of KRAS in our alliance with Professor Fesik and his team at Vanderbilt University and look forward to expanding our collaboration," said Clive R. Wood, Ph.D., senior corporate vice president, discovery research at Boehringer Ingelheim. "With new technologies and the scientific discoveries made by Professor Fesik's laboratory, we believe the time is now right to step up research efforts to develop novel cancer treatments that work by attacking KRAS and associated signaling pathways."

"Professor Fesik is a pioneer in the discovery of small molecules that bind to and inhibit challenging drug target proteins. His partnership with Boehringer Ingelheim will expedite efforts to discover novel cancer treatments that work on KRAS," said Lawrence J. Marnett, Ph.D., the Mary Geddes Stahlman professor of cancer research, university professor of biochemistry and chemistry and dean of basic sciences for the Vanderbilt University School of Medicine.

Mutations in the genes that encode KRAS are among the most powerful and frequent cancer drivers. They contribute to some of the most aggressive and deadly cancers, including up to 25 percent of lung, 35-45 percent of colorectal and about 90 percent of pancreatic tumors. KRAS has been a particularly difficult protein to target and no effective treatments targeting KRAS have been developed since its discovery in human cancers more than 30 years ago. The development of the first molecules inhibiting KRAS activation promises huge potential for the development of improved cancer therapies, which would offer treating physicians unprecedented options to complement existing treatment regimens.

By researching multiple approaches including direct inhibition of KRAS and indirect inhibition via SOS, Boehringer Ingelheim aims to accelerate the discovery of novel targeted therapies. The new collaboration with Vanderbilt University further strengthens Boehringer Ingelheim's oncology pipeline, which focuses on tumor cell-directed cancer treatments, new approaches in immune oncology and their combinations. It underscores the companies’ commitment to pioneering emerging fields of research and working closely with its partners to accelerate the development of novel first-in-class, breakthrough medications that fit the needs of patients, caregivers and healthcare professionals.

About Boehringer Ingelheim in Oncology
Boehringer Ingelheim’s oncology research is driven by a passion to advance clinical practice and a determination to improve the lives of patients who are battling cancer. Through our own scientific innovation and partnerships, we are focused on discovering and providing novel best-in-class, breakthrough cancer medications that fit the needs of patients, caregivers and healthcare professionals. We have a clear strategy to become a leader in the field of lung cancer. Boehringer Ingelheim has successfully launched two products for NSCLC, which have been widely adopted and established as valuable additions to current clinical practice. Continuous insights and learnings from research and development are key parts of innovation and our way forward to advance clinical practice in lung cancer and other cancer types.

About Boehringer Ingelheim
Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently with a total of some 50,000 employees worldwide.

The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative "Making More Health" while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does.

In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.

Most Popular Now

Novartis confirms 5 year data for first and only f…

Novartis, a global leader in Immunology & Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase III long-term extension stud...

FDA approves Rituxan Hycela (rituximab and hyaluro…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela™ (rituximab and hyaluronidase human) for subcuta...

Merck Foundation established

Merck, a leading science and technology company, today announced the establishment of the Merck Foundation. Through this foundation Merck combines many of its corporate r...

Researchers develop microneedle patch for flu vacc…

A National Institutes of Health-funded study led by a team at the Georgia Institute of Technology and Emory University has shown that an influenza vaccine can produce rob...

Novartis Phase III study shows ACZ885 (canakinumab…

Novartis today announced topline results from the global Phase III CANTOS study investigating the efficacy, safety and tolerability of ACZ885 (canakinumab) in combination...

Jardiance® (empagliflozin) analysis reinforces est…

An analysis of pooled safety data from 15 studies plus 4 extension studies involving more than 12,500 adults with type 2 diabetes demonstrated treatment with Jardiance® (...

Systems pharmacology modelers accelerate drug disc…

Alzheimer's is a chronic neurodegenerative disease which leads to the senile cognitive impairment and memory loss. Every third person older than 70 years suffers from it...

Does the emperor have clothes?

Discovered more than two decades ago, the hormone leptin has been widely hailed as the key regulator of leanness. Yet, the pivotal experiments that probe the function of ...

Alzheimer's and Parkinson's spurred by same enzyme

Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors. But at ...

Merck awards €1.25 million to research projects th…

Merck, a leading science and technology company, today announced its commitment to award €1.25 million to research projects in the field of fertility, supporting the adva...

Trials show unique stem cells a potential asthma t…

A study led by scientists at Monash University has shown that a new therapy developed through stem cell technology holds promise as a treatment for chronic asthma. The Mo...

Researchers publish new findings on influence of h…

Poor diet is associated with 80% of colorectal cancer cases, but the exact pathways by which diet leads to cancer are not known. In a newly published study, Cleveland Cli...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]